P53 Maintains Genomic Stability by Preventing Interference between Transcription and Replication

Cell Reports

Volumn 15, Issue 1, 2016, Pages 132-146

  Yeo, Constance Qiao Xin ^a   Alexander, Irina ^a,b   Lin, Zhaoru ^a   Lim, Shuhui ^a   Aning, Obed Akwasi ^a   Kumar, Ramesh ^a,b   Sangthongpitag, Kanda ^c   Pendharkar, Vishal ^c   Ho, Vincent H B ^a   Cheok, Chit Fang ^a,b,d,e  

^a AGENCY FOR SCIENCE   (Singapore)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c Agency for Science   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GYRASE INHIBITOR; PROTEIN P53; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; DNA TOPOISOMERASE INHIBITOR; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL POPULATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE; GENETIC STABILITY; GENOMIC INSTABILITY; GROWTH INHIBITION; HCT116 CELL LINE; HUMAN; HUMAN CELL; MITOSIS; MOUSE; NONHUMAN; P53 GENE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; ANTAGONISTS AND INHIBITORS; GENETIC TRANSCRIPTION; GENETICS; HCT 116 CELL LINE; METABOLISM;

ANTIGENS, NEOPLASM; DNA REPLICATION; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; GENOMIC INSTABILITY; HCT116 CELLS; HUMANS; TOPOISOMERASE INHIBITORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84963588819     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.03.011     Document Type: Article

References (51)

1. Azvolinsky A., Giresi P.G., Lieb J.D., Zakian V.A. Highly transcribed RNA polymerase II genes are impediments to replication fork progression in Saccharomyces cerevisiae. Mol. Cell 2009, 34:722-734.
2. Bartkova J., Horejsí Z., Koed K., Krämer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
3. Bermejo R., Doksani Y., Capra T., Katou Y.M., Tanaka H., Shirahige K., Foiani M. Top1- and Top2-mediated topological transitions at replication forks ensure fork progression and stability and prevent DNA damage checkpoint activation. Genes Dev. 2007, 21:1921-1936.
4. Bermejo R., Capra T., Gonzalez-Huici V., Fachinetti D., Cocito A., Natoli G., Katou Y., Mori H., Kurokawa K., Shirahige K., Foiani M. Genome-organizing factors Top2 and Hmo1 prevent chromosome fragility at sites of S phase transcription. Cell 2009, 138:870-884.
5. Bester A.C., Roniger M., Oren Y.S., Im M.M., Sarni D., Chaoat M., Bensimon A., Zamir G., Shewach D.S., Kerem B. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 2011, 145:435-446.
6. Brady C.A., Jiang D., Mello S.S., Johnson T.M., Jarvis L.A., Kozak M.M., Kenzelmann Broz D., Basak S., Park E.J., McLaughlin M.E., et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011, 145:571-583.
7. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
8. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K.W., Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 1999, 104:263-269.
9. Burgess D.J., Doles J., Zender L., Xue W., Ma B., McCombie W.R., Hannon G.J., Lowe S.W., Hemann M.T. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2008, 105:9053-9058.
10. Castel S.E., Ren J., Bhattacharjee S., Chang A.Y., Sánchez M., Valbuena A., Antequera F., Martienssen R.A. Dicer promotes transcription termination at sites of replication stress to maintain genome stability. Cell 2014, 159:572-583.
11. Cheok C.F., Verma C.S., Baselga J., Lane D.P. Translating p53 into the clinic. Nat. Rev. Clin. Oncol. 2011, 8:25-37.
12. Christophorou M.A., Ringshausen I., Finch A.J., Swigart L.B., Evan G.I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 2006, 443:214-217.
13. Cortes Ledesma F., El Khamisy S.F., Zuma M.C., Osborn K., Caldecott K.W. A human 5'-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. Nature 2009, 461:674-678.
14. Curtin N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer 2012, 12:801-817.
15. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., Schurra C., Garre' M., Nuciforo P.G., Bensimon A., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
16. Dominguez-Sola D., Ying C.Y., Grandori C., Ruggiero L., Chen B., Li M., Galloway D.A., Gu W., Gautier J., Dalla-Favera R. Non-transcriptional control of DNA replication by c-Myc. Nature 2007, 448:445-451.
17. Fraser N.W., Sehgal P.B., Darnell J.E. Multiple discrete sites for premature RNA chain termination late in adenovirus-2 infection: enhancement by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole. Proc. Natl. Acad. Sci. USA 1979, 76:2571-2575.
18. Frederick C.A., Williams L.D., Ughetto G., van der Marel G.A., van Boom J.H., Rich A., Wang A.H. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 1990, 29:2538-2549.
19. Garnett M.J., McDermott U. Exploiting genetic complexity in cancer to improve therapeutic strategies. Drug Discov. Today 2012, 17:188-193.
20. Goh A.M., Coffill C.R., Lane D.P. The role of mutant p53 in human cancer. J. Pathol. 2011, 223:116-126.
21. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., Ditullio R.A., Kastrinakis N.G., Levy B., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
22. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
23. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
24. Hartsuiker E., Neale M.J., Carr A.M. Distinct requirements for the Rad32(Mre11) nuclease and Ctp1(CtIP) in the removal of covalently bound topoisomerase I and II from DNA. Mol. Cell 2009, 33:117-123.
25. Hatchi E., Skourti-Stathaki K., Ventz S., Pinello L., Yen A., Kamieniarz-Gdula K., Dimitrov S., Pathania S., McKinney K.M., Eaton M.L., et al. BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. Mol. Cell 2015, 57:636-647.
26. Heck M.M., Hittelman W.N., Earnshaw W.C. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc. Natl. Acad. Sci. USA 1988, 85:1086-1090.
27. Helmrich A., Ballarino M., Tora L. Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes. Mol. Cell 2011, 44:966-977.
28. Hu T., Chang S., Hsieh T. Identifying Lys359 as a critical residue for the ATP-dependent reactions of Drosophila DNA topoisomerase II. J. Biol. Chem. 1998, 273:9586-9592.
29. Jackson J.G., Pant V., Li Q., Chang L.L., Quintás-Cardama A., Garza D., Tavana O., Yang P., Manshouri T., Li Y., et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012, 21:793-806.
30. Jones R.M., Mortusewicz O., Afzal I., Lorvellec M., García P., Helleday T., Petermann E. Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress. Oncogene 2013, 32:3744-3753.
31. Kurz E.U., Douglas P., Lees-Miller S.P. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J. Biol. Chem. 2004, 279:53272-53281.
32. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119:861-872.
33. Li T., Kon N., Jiang L., Tan M., Ludwig T., Zhao Y., Baer R., Gu W. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012, 149:1269-1283.
34. Lord C.J., Ashworth A. The DNA damage response and cancer therapy. Nature 2012, 481:287-294.
35. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74:957-967.
36. Murga M., Bunting S., Montaña M.F., Soria R., Mulero F., Cañamero M., Lee Y., McKinnon P.J., Nussenzweig A., Fernandez-Capetillo O. A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging. Nat. Genet. 2009, 41:891-898.
37. Murga M., Campaner S., Lopez-Contreras A.J., Toledo L.I., Soria R., Montaña M.F., D'Artista L., Schleker T., Guerra C., Garcia E., et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat. Struct. Mol. Biol. 2011, 18:1331-1335.
38. Murphy M., Ahn J., Walker K.K., Hoffman W.H., Evans R.M., Levine A.J., George D.L. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 1999, 13:2490-2501.
39. Nghiem P., Park P.K., Kim Y., Vaziri C., Schreiber S.L. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc. Natl. Acad. Sci. USA 2001, 98:9092-9097.
40. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., Crowley D., Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119:847-860.
41. Oren M., Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2010, 2:a001107.
42. Ray Chaudhuri A., Hashimoto Y., Herrador R., Neelsen K.J., Fachinetti D., Bermejo R., Cocito A., Costanzo V., Lopes M. Topoisomerase I poisoning results in PARP-mediated replication fork reversal. Nat. Struct. Mol. Biol. 2012, 19:417-423.
43. Reaper P.M., Griffiths M.R., Long J.M., Charrier J.D., Maccormick S., Charlton P.A., Golec J.M., Pollard J.R. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 2011, 7:428-430.
44. Schoppy D.W., Ragland R.L., Gilad O., Shastri N., Peters A.A., Murga M., Fernandez-Capetillo O., Diehl J.A., Brown E.J. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J. Clin. Invest. 2012, 122:241-252.
45. Subramanian D., Griffith J.D. p53 Monitors replication fork regression by binding to "chickenfoot" intermediates. J. Biol. Chem. 2005, 280:42568-42572.
46. Taylor W.R., Agarwal M.L., Agarwal A., Stacey D.W., Stark G.R. p53 inhibits entry into mitosis when DNA synthesis is blocked. Oncogene 1999, 18:283-295.
47. Toledo L.I., Murga M., Zur R., Soria R., Rodriguez A., Martinez S., Oyarzabal J., Pastor J., Bischoff J.R., Fernandez-Capetillo O. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol. 2011, 18:721-727.
48. Treszezamsky A.D., Kachnic L.A., Feng Z., Zhang J., Tokadjian C., Powell S.N. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res. 2007, 67:7078-7081.
49. Valente L.J., Gray D.H., Michalak E.M., Pinon-Hofbauer J., Egle A., Scott C.L., Janic A., Strasser A. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep. 2013, 3:1339-1345.
50. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431.
51. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 2002, 3:430-440.